Slide 1: Managing Director's Report 12 Months to 31 July 2020
For personal use only Managing Director’s Report 12 Months to 31 July 2020 18 September 2020
Slide 2: Vision and Mission Statement
For personal use only Vision and Mission Statement Vision To optimise the health and development of adults, infants and children. Mission To deliver science based bioactives which provide health benefits to adults, infants and children. 1
Slide 3: Full Year Performance Highlights
Full Year Performance Highlights For personal use only Total full year Revenue New products delivering $88.3m up 15% on growth in new segments and countries FY19 $76.7m driven by improved demand Inventory at $31.9m up Net Profit $12.5m up $4.2m on FY19 full year 23.6% on FY19 $10.1m. Balance Sh
Slide 4: COVID-19 Implications
COVID‐19 Implications For personal use only Our key focus has been and continues to be on the health and safety of our staff; COVID‐19 plans were executed in March and remain in place All customer demand has been met with additional care to maintain safety and higher inventory added to provide a
Slide 5: Full Year 2020 Results
For personal use only Full Year 2020 Results AUD million 4E Reported 4E Reported 15% year on year revenue growth 31 Jul 2020 31 Jul 2019 Revenue $88.3 $76.7 High growth rates EU, whilst Australia/NZ key sales region EBITDA $18.9 $14.0 EBITDA $18.9m (PY $14.0m) NPBT $17.7 $14.0 Fixed costs ma
Slide 6: Balance Sheet July 2020
Balance Sheet 31 July 2020 For personal use only AUD million Reported Reported Movement 31 Jul 2020 31 Jul 2019 Cash $9.2 $8.3 +$0.9m Cash balance strong $9.2m Trade Receivables $16.8 $18.4 ‐$1.6m Trade receivables Inventories $31.9 $27.7 +$4.2m down on FY19 Total Current Assets $59.1 $55.4 +$3.
Slide 7: Sales by Geography
Asia / Oceania sales A$000 Sales by Geography 80,000 25% For personal use only 60,000 20% 15% Sales across all key regions have grown 40,000 10% 20,000 during FY20 compared to FY19 5% 0 0% 2016 2017 2018 2019 2020 Asia & EU key growth areas for IF for Asia/Oceania sales CAGR the Chinese market,
Slide 8: Melody Dairies - New Zealand
Melody Dairies‐ New Zealand For personal use only Clover invested in a new company ‘Melody Dairies’ in 2019 which has built a new Nutritional Spray Dryer in Hamilton, New Zealand during 2020 Clover owns 42% of the equity and has access to 42% of the dryer capacity to manufacture its products T
Slide 9: An Update on Growth Platforms
For personal use only An Update on Growth Platforms Focus on Infant Formula New New Product Market Development Development 8
Slide 10: Growth Platform: New products driving future growth
Growth Platform For personal use only New products driving future growth Research & Development has a range of new products that have been created to fulfil customer requirements that will continue to deliver growth in the future. Clover’s concentrated DHA powders have won additional business in
Slide 11: Growth Platform: Infant formula maintains growth
Focus on For personal use only Infant Growth Platform Formula Infant formula maintains growth EU legislation has taken effect requiring a minimum of 20mg/100Kcal of DHA, positively impacting EU sales China business has continued to grow, providing many customers with improved results and demand
Slide 12: Growth Platform: New market development
For personal use only Growth Platform New market development Clover has grown sales across all markets, increasing exposure to food segments and other applications The company is selling into Asia, EU and USA a “stick pack” ready‐to‐drink formula, and high DHA gummies are in production in all ma
Slide 13: 1HFY21 Outlook & Priorities
1HFY21 Outlook & Priorities For personal use only Our people continue to be a major focus Uncertainty from COVID‐19 has the potential to impact demand both positively and negatively The higher pantry‐stocking driven demand of Q3 & Q4 FY20 may have been a ‘one‐off’, with demand in 1HFY21 appear
Slide 14: Disclaimer
For personal use only Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s